

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
31 August 2023 (31.08.2023)



(10) International Publication Number
WO 2023/163988 A1

(51) International Patent Classification:

A61K 9/20 (2006.01) A61K 31/7068 (2006.01)
A61K 9/28 (2006.01) A61K 45/06 (2006.01)
A61K 9/48 (2006.01) A61P 35/00 (2006.01)
A61K 31/706 (2006.01) A61P 35/02 (2006.01)

(21) International Application Number:

PCT/US2023/013614

(22) International Filing Date:

22 February 2023 (22.02.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/312,712 22 February 2022 (22.02.2022) US
63/312,714 22 February 2022 (22.02.2022) US
63/377,312 27 September 2022 (27.09.2022) US

(71) Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
[JP/JP]; 2-9 Kanda Tsukasa-Machi, Chiyoda-Ku, Tokyo,
Tokyo 101-8535 (JP).

(72) Inventors: DAVAR, Nipun; c/o Astex Pharmaceuticals,
Inc., 4420 Rosewood Drive, Suite 200, Pleasanton, Califor-
nia 94588 (US). KOU, Jim; c/o Astex Pharmaceuticals,
Inc., 4420 Rosewood Drive, Suite 200, Pleasanton, Califor-
nia 94588 (US). JAIN, Rachna; c/o Astex Pharmaceuticals,
Inc., 4420 Rosewood Drive, Suite 200, Pleasanton, Califor-
nia 94588 (US).

(74) Agent: TANNER, Lorna L. et al.; Sheppard Mullin
Richter & Hampton LLP, 650 Town Center Drive, 10th
Floor, Costa Mesa, California 92626-1993 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

(54) Title: COMBINATION FORMULATION OF CEDAZURIDINE




FIG. 1

(57) Abstract: The present disclosure relates generally to pharmaceutical dosage forms comprising azacitidine and cedazuridine.

[Continued on next page]

Published:

— with international search report (Art. 21(3))